drugset / Trial / NCT02072096

A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM)

NCT02072096

Phase 4 Terminated 192 enrolled Eli Lilly and Company
RandomizedParallel-groupOpen-labelTreatment

Summary

The main purpose of this study is to compare the benefits and risks associated with the use of 2 treatment strategies to lower blood sugar in participants aged 65 and older with T2DM. One strategy is based on the use of oral and injectable medications that only reduce blood sugar (glucose) when it is high. The other strategy is based on non-glucose dependent agents. The trial will last up to 72 weeks for each participant.

Timeline

Start
2014-02
Primary completion
2015-10
Completion
2015-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Exenatide Peptide Subcutaneous
Comparator Glimepiride Small molecule Oral
Subject Liraglutide Peptide Subcutaneous
Comparator insulin glargine Protein / enzyme biologic Subcutaneous
Background Acarbose Unknown Oral
Background Linagliptin Small molecule Oral
Background Metformin Small molecule Oral
Background Pioglitazone Small molecule Oral
Background Sitagliptin Small molecule Oral